LT2408476T - Žmogaus imunodeficito virusą (živ) neutralizuojantys antikūnai - Google Patents

Žmogaus imunodeficito virusą (živ) neutralizuojantys antikūnai

Info

Publication number
LT2408476T
LT2408476T LTEP10722810.8T LT10722810T LT2408476T LT 2408476 T LT2408476 T LT 2408476T LT 10722810 T LT10722810 T LT 10722810T LT 2408476 T LT2408476 T LT 2408476T
Authority
LT
Lithuania
Prior art keywords
hiv
immunodeficiency virus
human immunodeficiency
neutralizing antibodies
neutralizing
Prior art date
Application number
LTEP10722810.8T
Other languages
English (en)
Inventor
Po-Ying Chan-Hui
Jennifer Mitcham
Ole Olsen
Steven Frey
Matthew Moyle
Sanjay K. Phogat
Dennis R. Burton
Laura Marjorie Walker
Pascal Raymond Georges Poignard
Melissa D. DE JEAN DE ST.MARCEL SIMEK-LEMOS
Wayne KOPF
Stephen KAMINSKY
Original Assignee
Theraclone Sciences, Inc.
The Scripps Research Institute
International Aids Vaccine Initiative
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraclone Sciences, Inc., The Scripps Research Institute, International Aids Vaccine Initiative filed Critical Theraclone Sciences, Inc.
Publication of LT2408476T publication Critical patent/LT2408476T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP10722810.8T 2009-03-17 2010-03-17 Žmogaus imunodeficito virusą (živ) neutralizuojantys antikūnai LT2408476T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16101009P 2009-03-17 2009-03-17
US16582909P 2009-04-01 2009-04-01
US22473909P 2009-07-10 2009-07-10
US28566409P 2009-12-11 2009-12-11
PCT/US2010/027695 WO2010107939A2 (en) 2009-03-17 2010-03-17 Human immunodeficiency virus (hiv) -neutralizing antibodies

Publications (1)

Publication Number Publication Date
LT2408476T true LT2408476T (lt) 2018-03-26

Family

ID=42668183

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10722810.8T LT2408476T (lt) 2009-03-17 2010-03-17 Žmogaus imunodeficito virusą (živ) neutralizuojantys antikūnai

Country Status (16)

Country Link
US (8) US9051362B2 (lt)
EP (5) EP4085925A1 (lt)
AU (5) AU2010226668B2 (lt)
CA (2) CA2755821C (lt)
CY (1) CY1121323T1 (lt)
DK (1) DK2408476T3 (lt)
ES (4) ES2916404T3 (lt)
HR (1) HRP20180027T1 (lt)
HU (1) HUE036031T2 (lt)
LT (1) LT2408476T (lt)
NO (1) NO2408476T3 (lt)
PL (4) PL3260136T3 (lt)
PT (4) PT3260136T (lt)
SI (4) SI3260136T1 (lt)
SM (1) SMT201800016T1 (lt)
WO (1) WO2010107939A2 (lt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
WO2011092593A2 (en) * 2010-01-20 2011-08-04 Institute For Research In Biomedicine Hiv-1 neutralizing antibodies and uses thereof
WO2011109511A2 (en) * 2010-03-02 2011-09-09 International Aids Vaccine Initiative Novel hiv-1 envelope glycoprotein
CA3249351A1 (en) 2010-08-31 2025-07-03 Theraclone Sciences, Inc. Neutralizing antibodies against human immunodeficiency viruses (HIV)
ES2618380T3 (es) * 2010-09-24 2017-06-21 International Aids Vaccine Initiative Novedosos anticuerpos con amplio poder neutralizante de VIH-1
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
EP2739300B1 (en) 2011-07-05 2019-06-19 Duke University N-terminal deleted gp120 immunogens
US8791108B2 (en) * 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013039792A1 (en) 2011-09-12 2013-03-21 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogens based on an hiv-1 gp120 v1v2 epitope
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
CA2858347C (en) * 2011-12-05 2020-07-07 New York University V1v2 immunogens
AU2012347453B2 (en) 2011-12-08 2017-11-23 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
EP2828294A1 (en) * 2012-03-23 2015-01-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use
EP2698377A1 (en) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
US20160002319A1 (en) * 2013-02-28 2016-01-07 Therabioli, Inc. HIV Antigens and Antibodies
US20160130328A1 (en) * 2013-06-17 2016-05-12 Emory University Pathogen Binding Agents Conjugated to Radioisotopes and Uses in Imaging and Therapeutic Applications
WO2015048517A1 (en) * 2013-09-28 2015-04-02 Duke University Escape mutants
WO2015127108A1 (en) * 2014-02-19 2015-08-27 Duke University Trimeric hiv-1 envelopes compositions and uses thereof
US10093720B2 (en) * 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
CA2960436C (en) 2014-09-16 2021-01-05 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2016054053A2 (en) * 2014-09-29 2016-04-07 Duke University Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
HK1257270A1 (zh) 2015-09-15 2019-10-18 Gilead Sciences, Inc. 用於治疗hiv的toll样受体(tlr)调节剂
AU2016326738B2 (en) 2015-09-24 2023-08-31 Abvitro Llc HIV antibody compositions and methods of use
UA125819C2 (uk) 2015-12-15 2022-06-15 Гіліад Сайєнсіз, Інк. ВИДІЛЕНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО, ЩО ЗВ'ЯЗУЄТЬСЯ З gp120 ВІРУСУ ІМУНОДЕФІЦИТУ ЛЮДИНИ
CN107022027B (zh) * 2016-02-02 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
CN107033241B (zh) * 2016-02-03 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
US20200172601A1 (en) * 2017-06-22 2020-06-04 University Of Maryland, Baltimore Broadly neutralizing antibodies against hiv
HRP20250618T1 (hr) 2018-07-03 2025-07-18 Gilead Sciences, Inc. Protutijela koja ciljaju na hiv gp120 i postupci za uporabu
US12365722B2 (en) 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
JP7483234B2 (ja) 2018-12-04 2024-05-15 ザ ロックフェラー ユニバーシティー Ｈｉｖワクチン免疫原
CN114761041A (zh) 2019-07-16 2022-07-15 吉利德科学公司 Hiv疫苗及其制备和使用方法
EP4051318A4 (en) * 2019-10-29 2023-10-11 International AIDS Vaccine Initiative ENGINEERED ANTI-ENV HIV ANTIBODIES
US20210277093A1 (en) * 2020-03-09 2021-09-09 Adma Biologics, Inc. Immunotherapeutic compositions and methods of production for coronavirus
US12195524B2 (en) 2020-08-25 2025-01-14 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting HIV and methods of use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022162009A1 (en) 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies
WO2022161597A1 (en) * 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies
US20240181051A1 (en) * 2021-04-19 2024-06-06 The Wistar Institute Of Anatomy And Biology Sialydase linked hiv antibodies and methods of use
CN119677546A (zh) 2022-07-12 2025-03-21 吉利德科学公司 Hiv免疫原性多肽和疫苗及其用途
WO2026039311A1 (en) 2024-08-10 2026-02-19 Vectorgen Lentiviral vector for treating human immunodeficiency virus infection

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
DE69132709T2 (de) 1990-06-29 2002-06-20 Large Scale Biology Corp., Vacaville Melaninproduktion durch transformierte mikroorganismen
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
JPH10511085A (ja) 1994-12-02 1998-10-27 カイロン コーポレイション 二重特異性抗体を用いる免疫応答を促進する方法
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
EP1588166A4 (en) 2003-01-09 2007-06-27 Macrogenics Inc VECTOR SYSTEM WITH DOUBLE EXPRESSION FOR EXPRESSING ANTIBODIES IN BACTERIAL AND MAMMAL CELLS
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US20070292390A1 (en) * 2004-10-29 2007-12-20 Dimitrov Dimiter S Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
CA3249351A1 (en) * 2010-08-31 2025-07-03 Theraclone Sciences, Inc. Neutralizing antibodies against human immunodeficiency viruses (HIV)

Also Published As

Publication number Publication date
EP3542817A1 (en) 2019-09-25
EP2408476B1 (en) 2017-10-18
US12018067B2 (en) 2024-06-25
AU2015234345B2 (en) 2017-09-21
US20190169273A1 (en) 2019-06-06
AU2020210242A1 (en) 2020-08-20
AU2015234345C1 (en) 2017-12-21
PL3542817T3 (pl) 2022-09-19
US9920111B2 (en) 2018-03-20
AU2015234345A1 (en) 2015-11-05
CA2980883C (en) 2020-12-29
US20230295278A1 (en) 2023-09-21
SI3542817T1 (sl) 2022-09-30
PL3323427T3 (pl) 2021-10-11
HRP20180027T1 (hr) 2018-04-20
US20110044994A1 (en) 2011-02-24
EP4085925A1 (en) 2022-11-09
EP3260136A1 (en) 2017-12-27
US20190031742A1 (en) 2019-01-31
US10865234B2 (en) 2020-12-15
SMT201800016T1 (it) 2018-03-08
HUE036031T2 (hu) 2018-06-28
US11584789B2 (en) 2023-02-21
ES2848555T3 (es) 2021-08-10
EP3323427B1 (en) 2021-01-13
CY1121323T1 (el) 2020-05-29
ES2656234T3 (es) 2018-02-26
AU2023204017B2 (en) 2026-04-09
AU2010226668A1 (en) 2011-10-06
ES2916404T3 (es) 2022-06-30
PT3260136T (pt) 2021-02-12
SI2408476T1 (en) 2018-04-30
US20190338017A1 (en) 2019-11-07
AU2010226668B2 (en) 2015-07-16
AU2023204017A1 (en) 2023-07-13
WO2010107939A3 (en) 2011-05-26
PT3323427T (pt) 2021-03-03
AU2020210242B2 (en) 2023-04-06
AU2017264985B2 (en) 2020-05-07
CA2980883A1 (en) 2010-09-23
EP2408476A2 (en) 2012-01-25
US20150218257A1 (en) 2015-08-06
PT2408476T (pt) 2018-01-19
WO2010107939A2 (en) 2010-09-23
CA2755821C (en) 2017-11-14
US10239934B2 (en) 2019-03-26
PT3542817T (pt) 2022-07-05
DK2408476T3 (en) 2018-01-22
CA2755821A1 (en) 2010-09-23
SI3260136T1 (sl) 2021-05-31
US10407493B2 (en) 2019-09-10
EP3542817B1 (en) 2022-05-11
EP3260136B1 (en) 2020-11-25
NO2408476T3 (lt) 2018-03-17
PL2408476T3 (pl) 2018-05-30
SI3323427T1 (sl) 2021-07-30
EP3323427A1 (en) 2018-05-23
US20210040186A1 (en) 2021-02-11
US12312396B2 (en) 2025-05-27
AU2017264985A1 (en) 2017-12-07
PL3260136T3 (pl) 2021-10-18
ES2848203T3 (es) 2021-08-05
US20240343782A1 (en) 2024-10-17
US9051362B2 (en) 2015-06-09

Similar Documents

Publication Publication Date Title
PL2408476T3 (pl) Przeciwciała neutralizujące ludzkiego wirusa niedoboru odporności (HIV)
PT3556396T (pt) Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
AU2016202543A1 (en) Human immunodeficiency virus (hiv)-neutralizing antibodies
AP2011005944A0 (en) Inhibitors of human immunodeficiency virus replication.
DK3329772T3 (da) Dobbeltvektor til inhibering af human immundefektvirus
ZA201202116B (en) Neutralizing antibodies to hiv-1 and their use
IL222228A0 (en) Hiv vaccine
ZA201002445B (en) Hiv preventive vaccine based on hiv specific antibodies
IL212311A0 (en) Immunoenhancer-linked oligomeric hiv vaccines
AP2013007180A0 (en) Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
EP2635300A4 (en) DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV)
IL216102A0 (en) Combined measles-malaria vaccine
ZA201105357B (en) Splitting gp41
GB0912950D0 (en) Virus
HUE036963T2 (hu) Eljárások, kompozíciók és készletek humán immundeficiencia vírus (HIV) meghatározásához
GB0901056D0 (en) Virus
AP3595A (en) Novel gp41 antigens
GB0911339D0 (en) Viral file transfer
HK1178550A (en) Human group p immunodeficiency virus and uses thereof
GB201005057D0 (en) HIV-1 ENV-deactivating alpha-bodies
GB0920319D0 (en) HPV vaccine
GB0918366D0 (en) Viral inactivation
HK1184368A (en) Recombinant subunit dengue virus vaccine
ZA201107971B (en) Combined measles-malaria vaccine